Patient advocates and experts raise alarm over safety of Neurocrine Biosciences rare disease drug

Two months after an open letter highlighted possible safety issues, patient advocacy groups and several experts are publicly voicing growing alarm about a rare disease therapy marketed by Neurocrine Biosciences.

The concerns focus on perceived risks associated with the drug, prompting calls for closer scrutiny of its safety profile. While the article does not detail specific adverse events, the heightened attention suggests that stakeholders are uneasy about the therapy's risk‑benefit balance.

The column also touches on other industry topics, including a hospital group's lawsuit to block a federal 340B rebate pilot and ongoing discussions about pharmaceutical payments to physicians, but the primary story centers on the mounting safety worries surrounding the Neurocrine product.